TRANSCEND and TRIUMPH Trials
The TRANSCEND and TRIUMPH Phase 3 clinical trial programs evaluate retatrutide, an investigational GIP, GLP-1 and glucagon receptor agonist, in adults with type 2 diabetes, overweight or obesity.
-
Professor Jonathan E. Campbell
Exploring how glucagon receptor agonism adds to the metabolic effects of GIP and GLP-1 agonism.
-
Dr Harpreet S. Bajaj
Phase 3 retatrutide results in adults with T2D.
-
Professor Ania Jastreboff
Phase 3 results for retatrutide, a GIP, GLP-1 and glucagon receptor agonist, in obesity.
